News Home

Should You Buy Morphosys Ag (MOR) Stock on Thursday?

Thursday, August 18, 2022 09:48 AM | InvestorsObserver Analysts
Should You Buy Morphosys Ag (MOR) Stock on Thursday?

The market has been down on Morphosys Ag (MOR) stock recently. MOR gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Morphosys Ag has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MOR!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With MOR Stock Today?

Morphosys Ag (MOR) stock is lower by -3.09% while the S&P 500 is higher by 0.01% as of 9:39 AM on Thursday, Aug 18. MOR is lower by -$0.17 from the previous closing price of $5.51 on volume of 13,407 shares. Over the past year the S&P 500 is down -3.91% while MOR is lower by -59.94%. MOR lost -$6.34 per share in the over the last 12 months.

More About Morphosys Ag

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Click Here to get the full Stock Report for Morphosys Ag stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App